文章基本信息

标题：An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
本地全文：下载
作者：Xin Gan ; Qianqian Shan ; He Li 等
期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2022
卷号：119
期号：32
DOI：10.1073/pnas.2200879119
语种：English
出版社：The National Academy of Sciences of the United States of America
摘要：Significance This article describes a fully human therapeutic heavy chain–only antibody for anti-tumor treatment. We show that this anti-CTLA-4 antibody, HCAb 4003-2, has advantageous properties and stimulates anti-tumor T cell activation in several ways: 1) It binds human CTLA4 with high affinity; 2) it effectively depletes tumor-resident regulatory T cells, leading to enhanced antibody-dependent cellular cytotoxicity (ADCC); 3) with its small size, it shows potent tumor penetration, thereby more widely exerting its effect on T cell activation; and 4) the enhanced efficacy combined with the shorter serum half-life and less systemic drug exposure in vivo potentially provides an improved therapeutic window in clinical applications. The value of anti-CTLA-4 antibodies in cancer therapy is well established. However, the broad application of currently available anti-CTLA-4 therapeutic antibodies is hampered by their narrow therapeutic index. It is therefore challenging and attractive to develop the next generation of anti-CTLA-4 therapeutics with improved safety and efficacy. To this end, we generated fully human heavy chain–only antibodies (HCAbs) against CTLA-4. The hIgG1 Fc domain of the top candidate, HCAb 4003-1, was further engineered to enhance its regulatory T (T reg) cell depletion effect and to decrease its half-life, resulting in HCAb 4003-2. We tested these HCAbs in in vitro and in vivo experiments in comparison with ipilimumab and other anti-CTLA4 antibodies. The results show that human HCAb 4003-2 binds human CTLA-4 with high affinity and potently blocks the binding of B7-1 (CD80) and B7-2 (CD86) to CTLA-4. The results also show efficient tumor penetration. HCAb 4003-2 exhibits enhanced antibody-dependent cellular cytotoxicity function, lower serum exposure, and more potent anti-tumor activity than ipilimumab in murine tumor models, which is partly driven by a substantial depletion of intratumoral T regs. Importantly, the enhanced efficacy combined with the shorter serum half-life and less systemic drug exposure in vivo potentially provides an improved therapeutic window in cynomolgus monkeys and preliminary clinical applications. With its augmented efficacy via T reg depletion and improved safety profile, HCAb 4003-2 is a promising candidate for the development of next generation anti-CTLA-4 therapy.
关键词：enHCAbanti-CTLA-4 AbADCC killingintratumoral Tregdepletionanti-tumor efficacy